Celldex Therapeutics CLDX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $15K-87.6% | $121K— | $0-100% | $730K+5.0% | $695K-40.9% | ||
| $73M-3.1% | $75.33M+19.7% | $62.93M+16.1% | $54.2M+3.0% | $52.61M+12.1% | ||
| $11.45M-4.1% | $11.94M+11.7% | $10.69M+2.8% | $10.39M-4.0% | $10.82M+5.4% | ||
| $84.45M-3.2% | $87.27M+18.6% | $73.62M+14.0% | $64.59M+1.8% | $63.43M+10.9% | ||
| -$84.44M+3.1% | -$87.15M-18.4% | -$73.62M-15.3% | -$63.86M-1.8% | -$62.74M-12.0% | ||
| -562,900%-490,873pp | -72,027.3%— | —— | -8,747.5%+280pp | -9,027.2%-4,259pp | ||
| -$78.69M+3.2% | -$81.32M-21.3% | -$67.04M-18.5% | -$56.6M-5.2% | -$53.8M-14.2% | ||
| -524,566.7%-457,363pp | -67,204.1%— | —— | -7,753.4%-13.0pp | -7,740.4%-3,733pp | ||
| -$1.18+4.1% | -$1.23-21.8% | -$1.01-18.8% | -$0.85-4.9% | -$0.81-14.1% | ||
| -$83.58M+3.2% | -$86.34M-18.6% | -$72.79M-15.6% | -$62.98M-1.8% | -$61.87M-12.1% | ||
| -557,206.7%-485,854pp | -71,352.9%— | —— | -8,627.9%+275pp | -8,902.4%-4,204pp | ||
| -$84.44M+3.1% | -$87.15M-18.4% | -$73.62M-15.3% | -$63.86M-1.8% | -$62.74M-12.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Celldex Therapeutics's revenue?
- Celldex Therapeutics (CLDX) generated $866.0K in revenue over the trailing twelve months, down 88.5% year over year.
- Is Celldex Therapeutics profitable?
- Celldex Therapeutics is not currently profitable: it reported a net loss of $283.6M over the trailing twelve months, a -32753.6% net margin.
- What is Celldex Therapeutics's earnings per share?
- Celldex Therapeutics's diluted EPS over the trailing twelve months is $-4.27.
- Where does Celldex Therapeutics's income statement data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
